-+ 0.00%
-+ 0.00%
-+ 0.00%

Acadia reports additional Phase 2 data showing remlifanserin efficacy signal in Alzheimer's psychosis

PUBT·11/17/2026 14:06:22
Listen to the news
Acadia reports additional Phase 2 data showing remlifanserin efficacy signal in Alzheimer's psychosis
  • Acadia Pharmaceuticals presented additional Phase 2 RADIANT results for remlifanserin in Alzheimer's disease psychosis at the 2026 CTAD conference.
  • Once-daily 60 mg showed consistent benefits across psychosis measures, despite narrowly missing the primary endpoint; the key secondary endpoint achieved nominal significance.
  • Estimated treatment effects increased with baseline psychosis severity, while the 30 mg dose showed minimal benefit over placebo.
  • Safety findings were consistent with earlier results, with no negative impact on cognition or motor symptoms versus placebo.
  • Phase 3 development for Alzheimer's disease psychosis continues based on the Phase 2 findings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611170904BIZWIRE_USPR_____20261117_BW902690) on November 17, 2026, and is solely responsible for the information contained therein.